Almirall SA · BME:ALM

Almirall SA — Non-Deal Roadshow (November 2008)

47 slides from Almirall SA's roadshow presentation, November 2008

  1. Slide 1: Almirall moving forward with aclidinium bromide

    Almirall moving forward with aclidinium bromide November 2008

  2. Slide 2: Disclaimer

    Disclaimer This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are "forward-looking statements". These statements are based on currently available information and on best estimates and assumptio

  3. Slide 3: Dr. Jorge Gallardo, Chairman and CEO

    Dr. Jorge Gallardo Chairman and Chief Executive Officer 3

  4. Slide 4: Almirall – Focus on growth and value creation

    Almirall – Focus on growth and value creation Corporate vision Almirall aims to become a reference mid-cap R&D–driven pharma player by strengthening its Pan-European presence and expanding its global footprint through organic and non-organic growth In line to meet the guidance Total Net Sales of dou

  5. Slide 5: Almirall – Solid fundamentals for innovation and growth

    Almirall – Solid fundamentals for innovation and growth Value sources Strategic position Drivers for growth Capabilities / Opportunities ƒ #1 Spanish pharma, #3 in ƒ Broadest and deepest ƒ R&D capabilities in Spanish market. pipeline in company Respiratory, Autoinmune history. and Dermatology ƒ #1 d

  6. Slide 6: Almirall – Solid fundamentals for innovation and growth

    Almirall – Solid fundamentals for innovation and growth Corporate Strategy Corporate Strategy Strategic position Leveraging R&D LONG- Growing TERM Drivers for growth internationally VALUE Defending CREATION Spanish Leadership Opportunities / Capabilities 6

  7. Slide 7: Almirall since IPO

    Almirall since IPO Consistency and alignment with strategic goals Actual Estimate ’06 ’07 ‘08 ƒ Defend leadership position in Spain: In line with - Net sales 517,1 521,3 guidance - Headcount1 791 799 800 - Market share 5,7% 5,6% 5.5%2 ƒ International expansion: - Affiliates sales 161,0 186,4 In line

  8. Slide 8: Almirall as investment case

    Almirall as investment case Solid fundamentals focused on long term value creation Combining a well-established business … …with significant upside from pipeline ƒ Branded, patented balanced portfolio. ƒ Broadest and deepest pipeline in company history. ƒ Spanish leadership. ƒ Proven resilience to a

  9. Slide 9: Mr. Luciano Conde, Chief Operating Officer

    Mr. Luciano Conde Chief Operating Officer 9

  10. Slide 10: Market companies and Spain are the growth drivers in 2008

    Market companies and Spain are the growth drivers in 2008 2007 acquisitions driving international sales growth. On track to reach 2008 target. Net Sales Derma Sales to licensees in € million distribution/manufacturing Japan (Ebastine) and US agreements (Almotriptan) affected by 590,3 685,2 seasonali

  11. Slide 11: Net Sales breakdown by Top Products

    Net Sales breakdown by Top 10 Products YTD YTD % var YTD Q3 € thousand Q3 2008 Q3 2007 08 vs 07 Ebastine 81.496 84.187 -3,2% Atorvastatin (Prevencor) 77.602 68.871 12,7% Salmeterol & Fluticasone (Plusvent) 44.538 47.657 -6,5% Aceclofenac (Airtal) 38.413 39.389 -2,5% Venlafaxine (Dobupal) € 430M 36.8

  12. Slide 12: Almirall has a track record of balancing issues with new opportunities

    Almirall has a track record of balancing issues with new opportunities 2005 2006 2007 2008 Moving forward Pantopan Hermal • Roll out of selected Hermal dermatology portfolio. license acquisition Opportunities for Italy Tesavel® • Launch of Solaraze and Vaniqa (new countries/new EU rights for Sativex

  13. Slide 13: Key take-aways from the base business

    Key take-aways from the base business • Resilient branded, patented and well balanced product portfolio. • Current portfolio single digit top line sales evolution expected for 2009 and 2010 (excluding new Corporate Development projects). • Increased dermatology area presence in the company portfolio

  14. Slide 14: Dr. Per Olof Andersson, Chief Scientific Officer

    Dr. Per Olof Andersson Chief Scientific Officer 14

  15. Slide 15: Proven R&D track record and competitive capabilities

    Proven R&D track record and competitive capabilities A focused strategy that balances risk and reward International R&D capabilities with proven track record • R&D expense above 15% of sales. • 3 R&D centers in Spain and Germany with 600 staff. • 40 years of R&D tradition, 7 international products l

  16. Slide 16: A transformational pipeline on track

    Auto-immune A transformational pipeline on track Respiratory Dermatology Pipeline Status (the right end of each bar represents status of development as of Nov 12th) Expected filing Preclinical Ph I Ph II Ph III Registration date Aclidinium bromide (AB) (anti-muscarinic) COPD 4Q’09-1Q’10 (US) - 2011

  17. Slide 17: ACCLAIM results

    ACCLAIM results Aclidinium bromide shown to improve lung function and was well tolerated in the ACCLAIM (I &II) pivotal trials with a desirable risk/benefit profile • Consistent statistically significant improvements in FEV1 (trough and peak). • Health related quality of life benefit. • Increased ti

  18. Slide 18: Aclidinium bromide Monotherapy - Regulatory Plans

    Aclidinium bromide Monotherapy - Regulatory Plans US • Consultation with FDA in early 2009 to review ACCLAIM I & II trial results and discuss filing and development plans. • Forest plans to file with ACCLAIM data in 4Q 2009 or 1Q 2010, pending FDA feedback. EU • Regulatory interactions starting 4Q 2

  19. Slide 19: Aclidinium bromide Monotherapy – Further Development Plans

    Aclidinium bromide Monotherapy – Further Development Plans • Continue monotherapy development with higher QD doses and/or bid dosing. • The adverse event profile from the ACCLAIM studies suggests that higher doses will be well tolerated. • New studies to be initiated to evaluate different dosing reg

  20. Slide 20: Aclidinium bromide – Combination Strategies

    Aclidinium bromide – Combination Strategies Formoterol combination • The ACCLAIM results facilitate and potentially accelerate a strategy to develop a twice daily aclidinium/formoterol combination. • Phase II program to be expanded to evaluate bid dosing. • Aiming to launch no later than 2-3 years a

  21. Slide 21: In EU, almost 90% of COPD treatments are BID

    In EU, almost 90% of COPD treatments are BID, Spiriva® is the only OD drug 2008 Once-daily 14% More than once-daily 86% BID dosing most common Base: Adelphi Data EU (excluding France) COPD patients n= 3019 2007 Source = PRF section F1 Question: Please list ALL drugs that the patient is receiving for

  22. Slide 22: About 65% of tiotropium prescriptions are combined with other respiratory products

    About 65% of tiotropium prescriptions are combined with other respiratory products Tiotropium co-prescriptions USA EUROPE (TOP 5) 40% 40% Advair Seretide/Symbicort 35% 35% 30% 30% 25% LABAs 25% 20% 20% LABAs 15% 15% ICS 10% ICS 10% 5% ICS 5% 0% 0% TIOTROPIUM CO-PRESCRIPTIONS TIOTROPIUM CO-PRESCRIPTI

  23. Slide 23: COPD LAMA market volume forecast

    COPD LAMA market volume forecast The LAMA market is the high growth COPD market. We forecast it to grow by 14% CAGR between 2007 and 2011, reaching 33% of the COPD market by volume in 2023. Key drivers: Events impacting the broader COPD market will impact the LAMA market. As such, increasing awarene

  24. Slide 24: COPD LAMA-LABA market volume forecast

    COPD LAMA-LABA market volume forecast We forecast the LAMA-LABA market to achieve a 20% share of the total COPD market by 2023. • The LAMA-LABA market has been modelled on Spiriva plus LABA- containing product co-prescriptions, representing 39% of Spiriva prescriptions for the past few years. Source

  25. Slide 25: Aclidinium Bromide: superior inhalation device

    Aclidinium Bromide: superior inhalation device Designed for compliance with global regulatory standards (FDA, EMEA, Japan) • Inhalation device based on technology already approved in the EU. • Design modifications agreed with FDA – ongoing interactions. • Experienced group of advisors used to ensure

  26. Slide 26: R&D newsflow

    R&D newsflow Aclidinium bromide • Q1’09 – FDA meeting. • May’09 – ATS – Further details on aclidinium bromide’s Phase III data. • During 2009, start of several aclidinium bromide clinical trials will be announced. Rest of Pipeline • Q1’09 – Sativex Phase III available (Spasticity). • H1’09 – New dat

  27. Slide 27: Mr. Eduardo Sanchiz, Chief Financial Officer

    Mr. Eduardo Sanchiz Chief Financial Officer 27

  28. Slide 28: Financial performance

    Financial performance • Sales CAGR’04-07: 4,2% • Consistent sales growth over the years. • Q3’07-Q3’08: 16% • Substantial Normalised Net Income growth CAGR’04-07: 14% despite R&D investments to support pipeline. Cash Flow from Operating Activities > €160M in 2006/07 • Strong Cash Flow generation. an

  29. Slide 29: Debt details

    Debt details Highlights Healthy Debt positions ƒ Term: 5 years. Q3’08 FY’08 Outlook ƒ No need to refinance. Nebt Debt * 190 <1 x EBITDA ƒ Combination of loan and credit line. Equity/Assets 47% * Excluding Pension plans Key takeaways ƒ Solid balance sheet with low Net Debt ƒ No need to refinance ƒ Ro

  30. Slide 30: Summary Income Statement

    Summary Income Statement CAGR % € MM 2004 2005 2006 2007 04-'07 Q3'07 Q3'08 % Net Sales 699,7 736,1 758,0 792,5 4,2% 590,3 685,2 16,1% % Change 3,5% 5,2% 3,0% 4,5% N.A. 16,1% Gross Profit 449,2 465,2 474,7 484,6 2,6% 368,8 435,8 18,2% % Margin 64,2% 63,2% 62,6% 61,1% 62,5% 63,6% Other Income 45,5 62

  31. Slide 31: Financial achievements vs. IPO key messages

    Financial achievements vs. IPO key messages IPO message: - Stable top line evolution, excluding acquisitions - High single digit earnings evolution - Recurrent Cash Flow Generation 2006 2007 2008 Outlook € Million Low double digit Sales 758 792 growth EBITDA 144,0 170,3 + 30% Normalized Net Income 1

  32. Slide 32: Expectations for closing 2008

    Expectations for closing 2008 Q4’08 envisages sales in line with Q3 but heavy expenditure both in R&D and SG&A as other years, leading to a 2008 Net Income in line with current market consensus (approx. €138M). • Group sales expected to grow at low double digit. • International Sales expected to acc

  33. Slide 33: Financial Outlook 2009

    Financial Outlook 2009 A brief to financial guidance in 2009 • 2009 P&L perspectives : − Expected single digit growth in sales, EBITDA and Normalised Net Income. − R&D expense to grow at single digit. − Pay-out policy to be maintained at 35-40% • Healthy financial structure not overleveraged 33

  34. Slide 34: Appendixes

    Appendixes 34

  35. Slide 35: Almirall - Growth, innovation and financial performance

    Almirall - Growth, innovation and financial performance Corporate profile and key facts Headquarters • A growing R&D-driven pharma company listed in 2007 – Founded in 1943. Headquartered in Barcelona, Spain. c 3,400 people worldwide. – # 1 Spanish pharma, #3 in Spanish market. – Diversified, branded

  36. Slide 36: A successful combination of R&D and business development

    A successful combination of R&D and business development The Almirall business model Income From Proprietary Products (45% in 2007) Income From Other Companies Products (55% in 2007) Out-licensing Almirall Markets Quid-pro-quo (15%) In-licensing (40%) Almirall has strategic Almirall has consolidated

  37. Slide 37: Worldwide direct presence and 2007 local sales

    Worldwide direct presence and 2007 local sales Poland Switzerland Belgium • Started in 2008 • Started in 2008 • Sales: € 10 MM Mexico • Sales: € 25 MM United Kingdom & Ireland • Started in 2008 Germany • Sales: € 21 MM France • Sales: € 68 MM Spain • Sales: € 521 MM Portugal Austria • Sales: € 10 MM

  38. Slide 38: Spanish pharma market: legislation and market trends

    Spanish pharma market : legislation and market trends Applicable Law Market trends (*) • The National Heath Service (SNS) is based on the principles of universal and equal access. It gives Spanish Market (Sales 000€) access to all citizens to a co-payment or free (elderly, chronic) scheme of medicin

  39. Slide 39: Almirall has proven its resilience…

    Almirall has proven its resilience… Sales (€ MM) 800 736 758 792 700 +3.0% +4.5% 271 676 + 5.1% 215 241 632 +3.6% +7.0% 169 583 +8.4% 161 600 141 470 +24.0% 140 515 531 521 517 521 99 491 400 443 371 200 0 2000 2001 2002 2003 2004 2005 2006 2007 Spanish Sales International and unassigned Sales Astud

  40. Slide 40: …in one of Europe's strongest branded markets

    …in one of Europe’s strongest branded markets New regulatory environment provides stable outlook Spanish pharma market reacts differently to generic launches compared to other major markets Branded Pharma in Spain Prozac Example – Post Generic Share Erosion Generic penetration has been small US Spai

  41. Slide 41: Other examples of low generic penetration in Spain

    Other examples of low generic penetration in Spain Genericisation occurs at varying speed Source: IMS Health MIDAS Market Segmentation MAT December 2007 41

  42. Slide 42: Spain: what happens when a generic gets to market

    Spain : what happens when a generic gets to market Process Resilience of spanish market to Generic penetration • The approval of a generic in the Spanish market • Historically low prices vs. European average triggers the creation of an homogeneous group. (some branded products are cheaper than gener

  43. Slide 43: Income Statement

    Income Statement Highlights YTD YTD % var YTD Q3 € Thousand Q3 08 Q3 07 08 vs 07 • Sales improvement driven by new portfolios. Net Sales 685.195 590.348 16,1% Gross Profit 435.849 368.825 18,2% • Gross profit improvement. % of sales 63,6% 62,5% Other Incom e 123.553 93.147 32,6% • Other Income incre

  44. Slide 44: Balance Sheet

    Balance Sheet YTD % YTD € Thousand Q3 08 of BS Dec 2007 Goodw ill 273.662 19,7% 274.258 Highlights Intangible assets 356.148 25,7% 383.448 • Increase of accounts Property, plant and equipment 172.672 12,4% 179.340 receivable, linked to the Financial assets 5.652 0,4% 6.298 Hermal, Shire’s portfolio

  45. Slide 45: Cash Flow

    Cash Flow YTD YTD € Thousand Q3 08 Q3 07 Profit Before Tax 157.355 144.746 Highlights Depreciation and amortisation 47.329 23.965 • Cash Flow from Operating Change in w orking capital -30.091 -56.204 Activities improved due to Other adjustments 19.079 38.521 D&A (linked to 2007 Cash Flow from Operat

  46. Slide 46: Contact details

    Contact details For further information, please contact: Jordi Molina, Head of Investor Relations Ph. +34 93 291 3087 jordi.molina@almirall.com Or visit our website: www.almirall.com

  47. Slide 47: (% Almirall

    Zé . (% Almirall Solutions with you in mind

Almirall — Non-Deal Roadshow (November 2008) on 6ix